Compare Citius Pharmaceuticals Inc (CTXR) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs NEOS S&P 500 High Income ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while NEOS S&P 500 High Income ETF trades at $53.65. The key difference: NEOS S&P 500 High Income ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | SPYI | |
|---|---|---|
Market Cap | $14.64M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $1.82 | $54.07 |
52-Week Low | $0.53 | $47.98 |
Enterprise Value | $10.86M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
SPYI trades at $53.37, down 0.61% on the day, with a bullish technical signal supported by moving averages. The NEOS S&P 500 High Income ETF has surpassed $10 billion in assets under management, driven by strong investor demand for its monthly income strategy. Recent dividend payments of $0.52-$0.54 demonstrate consistent distribution capabilities, while technical indicators show support at $53 and resistance at $54.
The ETF's covered-call strategy provides high monthly income with partial upside participation, making it attractive for income-focused investors. However, the 0.68% expense ratio and potential return of capital distributions present cost considerations. Market volatility benefits the options strategy, though competition with JEPI and other income ETFs remains a key factor.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
